Clive Seymour Joins Bruker Daltonics as Vice President for Asia-Pacific.Business Editors BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 26, 2004 Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces that Clive Seymour has been appointed as the Company's Vice President for Asia-Pacific, effective March 1st, 2004. Bruker Daltonics' business in Asia-Pacific has grown rapidly in recent years, based on innovative, high-quality products, and a strong commitment to customer service and support. Mr. Seymour will be responsible for the management of the Company's life-science sales and marketing, as well as all associated customer service and support operations in the Asia-Pacific Region, including Bruker Daltonics organizations in Australia, China/HK, Singapore/South-East Asia (Malaysia, Thailand, Vietnam, Laos, Cambodia, Philippines, Indonesia) and Taiwan, in addition to distribution channels covering South Korea and New Zealand New Zealand (zē`lənd), island country (2005 est. pop. 4,035,000), 104,454 sq mi (270,534 sq km), in the S Pacific Ocean, over 1,000 mi (1,600 km) SE of Australia. The capital is Wellington; the largest city and leading port is Auckland. . Bruker Daltonics K.K. is managed separately from its Yokohama, Japan headquarters. Frank Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, commented: "We are very pleased to have Clive join our team to manage the further growth in this large and diverse region. Clive brings a wealth of experience from a decade of managing life-science businesses in the Asia-Pacific region, and he has an excellent track record for sales growth and business expansion in developing markets. With a broad range of innovative life-science products and high-level customer support in the region, we are well positioned to offer our Asia-Pacific customers the tools needed for advanced drug discovery and development, as well as for cutting-edge molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller and clinical research." From March 1997 to February 2004, Mr. Seymour was Vice President Region Asia Pacific at Biacore AB, also assuming the roles of Head of Life Science Research Business Unit (2000) and Vice President Corporate Communications (2002). Previously, from 1992 to 1997, he was European Market Area Manager for Pharmacia Biotech Europe, and Regional Marketing and Sales Manager for Pharmacia Biotech Asia Pacific. "I am delighted to be joining Bruker Daltonics at such an exciting time in the growth of life-science applications of mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. ," commented Clive Seymour. "Asia-Pacific offers enormous potential for life-science solutions providers, with research and pharmaceutical development of high priority in the region. Bruker Daltonics has clearly demonstrated its commitment to innovation and customer support, and is delivering comprehensive applications-focused platforms to a number of fields, including expression proteomics, biomarker discovery, clinical proteomics and metabonomics. I am looking forward to joining this impressive organization to further develop and expand its Asia-Pacific operations." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion